Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (10) | Back to Search
Poor medication adherence in clinical trials: consequences and solutions
- In: Short Communications D1 on Tuesday, 23 May 2017, 11:15-12:30
- At: Stockholm (Sweden) (2017)
- Type: Presentation
- By: VRIJENS, Bernard (WestRock Healthcare & University of Liège, Belgium, Healthcare, Vise, Belgium)
- Co-author(s): Alasdair Breckenridge : Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
Jeffrey K Aronson: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
Terrence F Blaschke: Dept of Medicine, Stanford University School of Medicine, Stanford, United States
Dan Hartman : Global Health, Bill and Melinda Gates Foundation, Seattle, United States
Carl Peck: Dept of Bioengineering and Therapeutic Sciences, University of California, San Francisco, United States
Bernard Vrijens: Healthcare, WestRock , Vise, Belgium;Biostatistics, University of Liège, Liège, Belgium - Abstract:
Backgrounds
The crucial importance of patient adherence to medication was captured by the former US Surgeon General, C. Everett Koop when he said “Drugs don’t work in patients who don’t take them”. Patient adherence, defined as how drugs are taken as prescribed, involves three actions by the patient: initiation of therapy, implementation of the
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023